15th Feb 2016 16:15
SHIRE PLC - Director/PDMR ShareholdingSHIRE PLC - Director/PDMR Shareholding
PR Newswire
London, February 15
Director/PDMR Shareholding
February 15, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified today that, following the appointment of Bill Mordan as General Counsel and Company Secretary on October 1, 2015, and in accordance with the terms of his employment agreement, Mr. Mordan, a Person Discharging Managerial Responsibilities (“PDMR”), was granted a new hire award and a replacement equity award on February 12, 2016, under the Shire Long Term Incentive Plan 2015 (“LTIP”). The awards comprise restricted stock units (“RSUs”) and stock appreciation rights (“SARs”) in respect of notional American Depositary Shares (“ADSs”) as follows:
| Award type | Number of ADSs | Exercise price | Vesting date(s)(1) | |
| New hire award | RSUs(2) | 5,532 | Nil | October 1, 2018 |
| SARs | 6,147 | $154.95 | October 1, 2018 | |
| Replacement equity award(3) | RSUs | 10,326 | Nil | October 1, 2016 (50%); October 1, 2017 (50%) |
| RSUs(2) | 22,127 | Nil | October 1, 2018 |
The vesting dates reflect the relevant anniversaries of the originally intended date of grant of October 1, 2015. The vesting of each of the awards is subject to the fulfilment of service conditions.
The vesting of these RSUs is subject to the fulfilment of performance conditions.
The replacement equity award is intended to compensate Mr. Mordan for the equity awards he forfeited in connection with the termination of his previous employment.
The Company also announces it was notified today that Mark Enyedy, a PDMR, was granted a special equity award on February 12, 2016, in recognition of his performance of duties as Interim General Counsel and Company Secretary in addition to his existing responsibilities as Head of Corporate Development. The award comprises RSUs in respect of 2,130 notional ADSs and was granted under the LTIP. Subject to the fulfilment of service conditions, the award will vest in two tranches: 50% on October 1, 2016, and 50% on October 1, 2017; respectively, the first and second anniversaries of the originally intended date of grant of October 1, 2015.
No consideration was paid by Mr. Mordan or Mr. Enyedy in respect of their awards. One ADS is equal to three Ordinary Shares of 5 pence each in the Company.
This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
Oliver StrawbridgeSenior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Matthew Osborne | [email protected] | +1 781 482 9502 |
| Sarah Elton-Farr | [email protected] | +44 1256 894157 |
NOTES TO EDITORS
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
www.shire.com
Related Shares:
Shire